China, Oct. 27 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Real-world outcomes of adjuvant pembrolizumab in patients with high-risk clear-cell renal cell carcinoma after surgery'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600135128
Registration Time: 2026/10/26
Type: Observational study
Primary Sponsor: The Third Medical Center of Chinese People‘s Liberation Army General Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=349109
Published by HT Digital Content Services with permission from Health Daily Digest....